Archive

BioCapital Europe 2018, organised by LSP Friday, January 19th, 2018
BioCapital Europe 2018, an LSP (Life Sciences Partners) event, is delighted to announce its 16th consecutive event, taking place on 6th February 2018 in Amsterdam, The Netherlands. BioCapital Europe is Europe’s prem [...]
LSP reaches milestone: 10 years investing in listed Life Sciences Securities Wednesday, January 17th, 2018
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li [...]
FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis Thursday, January 11th, 2018
FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase 2 clinical trial (CALDOSE-1) Patients with active ulcerative colitis will [...]
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies Monday, January 8th, 2018
UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop an [...]
Takeda to acquire LSP portfolio company TiGenix Friday, January 5th, 2018
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs Thursday, January 4th, 2018
- IND submitted to U.S. FDA for MCLA-117 in AML - - First CTA approval for MCLA-158 received in European country -   UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a c [...]


2018
2017
2016
2015
2014
2013
2012
back to archive overview

Archive

BioCapital Europe 2018, organised by LSP Friday, January 19th, 2018
BioCapital Europe 2018, an LSP (Life Sciences Partners) event, is delighted to announce its 16th consecutive event, taking place on 6th February 2018 in Amsterdam, The Netherlands. BioCapital Europe is Europe’s prem [...]
LSP reaches milestone: 10 years investing in listed Life Sciences Securities Wednesday, January 17th, 2018
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li [...]
FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis Thursday, January 11th, 2018
FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase 2 clinical trial (CALDOSE-1) Patients with active ulcerative colitis will [...]
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies Monday, January 8th, 2018
UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop an [...]
Takeda to acquire LSP portfolio company TiGenix Friday, January 5th, 2018
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs Thursday, January 4th, 2018
- IND submitted to U.S. FDA for MCLA-117 in AML - - First CTA approval for MCLA-158 received in European country -   UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a c [...]


2018
2017
2016
2015
2014
2013
2012
back to archive overview